![Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram](https://www.researchgate.net/publication/233746224/figure/fig2/AS:601587995136000@1520441163001/Progression-free-survival-and-overall-survival-curves-for-all-patients-with-different.png)
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
![Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures | Radiation Oncology | Full Text Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures | Radiation Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13014-022-02186-0/MediaObjects/13014_2022_2186_Fig1_HTML.png)
Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures | Radiation Oncology | Full Text
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig1_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab](https://www.mdpi.com/cancers/cancers-12-03021/article_deploy/html/images/cancers-12-03021-g001-550.jpg)
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig2_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research
![Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41375-020-01042-y/MediaObjects/41375_2020_1042_Fig2_HTML.png)
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
![Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41571-023-00823-5/MediaObjects/41571_2023_823_Fig1_HTML.png)
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
![Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41571-023-00823-5/MediaObjects/41571_2023_823_Fig2_HTML.png)
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
![Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum](https://discourse.datamethods.org/uploads/default/original/2X/0/00c7385e94688a19921c14a15730ba55e0e5dd17.png)
Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum
![図3 Overall and disease-free survival curves of patients with initially unresectable disease who underwent 図3 Overall and disease-free survival curves of patients with initially unresectable disease who underwent](https://www.gi-cancer.net/gi/gi-pedia/vol04/img/z03.jpg)
図3 Overall and disease-free survival curves of patients with initially unresectable disease who underwent
![JCM | Free Full-Text | Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC JCM | Free Full-Text | Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC](https://www.mdpi.com/jcm/jcm-11-04433/article_deploy/html/images/jcm-11-04433-g003b.png)
JCM | Free Full-Text | Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC
![Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram](https://www.researchgate.net/publication/273956724/figure/fig2/AS:282745193418754@1444423115791/Comparison-of-disease-free-survival-DFS-and-overall-survival-OS-according-to-the.png)
Comparison of disease-free survival (DFS) and overall survival (OS)... | Download Scientific Diagram
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/RCT-of-Letrozole-in-Post-menopausal-breast-cancer.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure2-1.png)